
Opinion|Videos|June 26, 2024
Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial
Results from the monarchE trial are analyzed by Hope Rugo, MD, and Joyce O'Shaughnessy, MD.
Advertisement
Video content above is prompted by the following:
- Abemaciclib is recommended by NCCN in this setting based on the monarchE trial, which recently released its 5-year long-term data in January.
- Describe the updated survival data, including both invasive disease-free survival and overall survival. How have these survival rates evolved with each annual analysis?
- Please highlight the follow-up time of patients.
- Are there specific subgroups of patients within the monarchE trial who derived particular benefit from the addition of abemaciclib?
Advertisement
Related to this article

Faculty say heart failure patients miss iron deficiency care when no one owns it; pharmacist-led workflows may help close the gap.

The FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.

In a single-clinic study, 61.5% of patients with psoriasis screened positive for psoriatic arthritis using a validated questionnaire.

Pharmacy teams can shorten the time of Medicare GLP-1 Bridge approvals, but 2027 approval windows may leave patients without titration check-ins.

An employer coalition's new guide outlines how workplaces can prevent and manage diabetes, from benefit design to accommodations.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

Obinutuzumab (Gazyva) led to complete remission of proteinuria in more patients than tacrolimus did, according to the FDA.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer
2
Hepatitis B Screening Gaps Persist as Functional Cure Option Arrives
3
Complicated UTI Care Strained by Unclear Goals, Access Gaps
4
IgA Nephropathy, FSGS Care Needs Coordinators, Not Just New Drugs
5

